查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1677168

纖維化疾病藥物市場按類型、治療類型、給藥方法、治療階段和最終用戶分類 - 2025-2030 年全球預測

Fibrotic Diseases Treatment Market by Type, Treatment Type, Administration Method, Treatment Stage, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

纖維化疾病治療市場預計 2024 年價值 57.8 億美元，2025 年價值 61.3 億美元，複合年成長率為 6.46%，到 ​​2030 年達到 84.2 億美元。

主要市場統計數據
基準年 2024 年 57.8億美元
預計 2025 年 61.3億美元
預測年份 2030 84.2億美元
複合年成長率（%） 6.46%

纖維化疾病治療市場是醫療保健產業中一個充滿活力且不斷發展的領域，其特點是專注於對抗以組織疤痕和器官功能障礙為特徵的複雜疾病。多年來，不斷增加的研究、技術創新以及對疾病機制的更深入理解推動了治療方法的重大進步。這項綜合分析提供了強大而深入的市場洞察力，強調了各種纖維化疾病治療方法的臨床、治療和經濟意義。它詳細概況了重塑治療模式的關鍵促進因素、挑戰和新興趨勢。從臨床醫生到決策者的相關人員將發現接下來的討論非常有趣且富有洞察力，有助於闡明充滿挑戰和轉型機會的市場格局。

近年來，醫療保健系統見證了先進技術和個人化治療方法的快速融合，旨在更有效地針對纖維化途徑。這種轉變受到不斷變化的監管環境和對以患者為中心的方法日益關注的支持，為突破性的治療方法進展鋪平了道路。隨著慢性纖維化疾病的盛行率不斷上升，市場持續專注於創新、安全性和臨床效果。本報告中提出的分析旨在詳細了解這些動態，使相關人員能夠利用這個複雜領域中出現的機會。

改變治療模式

纖維化疾病治療領域正在經歷重大變革時期，幾種相互關聯的轉變正在重新定義市場。其中最主要的是臨床研究創新的爆發式成長，在闡明細胞機制和分子過程方面取得的突破導致了標靶治療的發展。這種演變不僅改變了治療通訊協定，而且還鼓勵採用更個人化的護理方法，以更緊密地滿足每個患者的需求。同時，人們正在大力推動數位健康解決方案的整合，以促進準確診斷和即時監測治療結果。

這些創新的採用促使監管機構重新審查和重組核准途徑，以確保新療法符合嚴格的安全性和有效性標準。產業相關人員、學術研究人員和醫療機構之間加強合作正在加速新治療方法的市場滲透，進一步凸顯了這些變化的變革性影響。這些因素的共同作用造成了這樣一種局面：傳統模式正受到科學主導、技術支持的護理模式的挑戰。隨著醫療保健提供者擴大利用巨量資料、人工智慧主導的分析和基因組學，改善患者治療效果和完善治療通訊協定變得更加切實。這種模式轉移強調精準醫療和自適應治療策略，體現了市場對不斷變化的臨床需求的反應，並強調了持續創新在重塑患者照護的關鍵作用。

纖維化疾病治療市場的關鍵細分見解

對纖維化疾病治療市場的詳細分析揭示出涵蓋臨床、技術和業務層面的多方面細分。基於類型的分割提供了對各種病理的深入了解，例如心臟纖維化、肝纖維化、肺纖維化和腎臟纖維化，每種病理都存在獨特的挑戰和治療考慮。這些區別對於制定介入策略和最佳化各種患者照護場景中的資源分配至關重要。

根據治療類型進一步分類包括傳統藥物治療、器官移植和創新氧氣療法技術。這種分類強調了治療方法的多樣性，反映了臨床實踐向更精細和更有針對性的方法的轉變。按給藥方式分類的市場代表了廣泛的應用技術，包括吸入、注射、靜脈注射、口服和局部，對應於不同的臨床核准和患者依從性模型。這種細分可作為理解每種技術所表現出的不同程度的侵入性、有效性和成本影響的藍圖。

此外，按治療階段進行細分可以讓您了解病人歷程在晚期纖維化、早期纖維化、末期器官衰竭和纖維化前階段的治療歷程，其中預防性治療是關鍵。這個維度強調了治療性介入的演變，並強調了早期診斷和預防管理對限制疾病進展的重要性。最後，基於最終用戶的細分突出了主要醫療保健環境（例如學術和研究機構、醫院和專科診所）的作用。這些環節對於傳播前沿臨床知識、協調護理和推動創新至關重要。綜合起來，這些細分提供了市場動態的詳細視圖，揭示了臨床需求、治療創新和醫療保健提供模式的關鍵交匯點。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 人口老化和生活方式因素導致纖維化疾病盛行率上升
      • 擴大全球醫療基礎設施將改善纖維化疾病藥物的獲取
      • 新型纖維化治療方法的支持性監管政策和快速核准途徑
    • 限制因素
      • 藥物開發和臨床試驗階段的高成本限制了新療法的獲得
    • 機會
      • 整合數位健康技術，增強疾病監測與治療順從性
      • 推動精準醫療和纖維化疾病的標靶治療方法
    • 任務
      • 新型纖維化治療方法的複雜監管核准流程與合規負擔
  • 市場區隔分析
    • 治療類型：增加治療纖維化疾病的藥物消費量
    • 最終用戶：學術研究機構更加關注纖維化疾病治療的早期研究
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 纖維化疾病藥物市場按類型

  • 心臟纖維化
  • 肝纖維化
  • 肺纖維化
  • 腎臟纖維化

7. 纖維化疾病藥物市場依治療類型分類

  • 藥物治療
  • 器官移植
  • 氧氣療法

8. 纖維化疾病藥物市場依給藥方式分類

  • 吸入
  • 注射
  • 靜脈
  • 口服
  • 話題

9. 纖維化疾病藥物市場（依治療階段分類）

  • 晚期纖維化
  • 纖維化的早期階段
  • 末期器官衰竭
  • 纖維化前期（預防性治療）

第 10 章 纖維化疾病藥物市場（依最終使用者）

  • 學術研究所
  • 醫院
  • 專科門診

11. 美國子宮肌瘤病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區纖維化疾病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲纖維化疾病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • AbbVie Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Ferring Pharmaceuticals Private Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ipsen Pharma
  • Kyorin Pharmaceutical Co., Ltd.
  • Mallinckrodt
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Santen Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: MRR-A40F58415FB7

The Fibrotic Diseases Treatment Market was valued at USD 5.78 billion in 2024 and is projected to grow to USD 6.13 billion in 2025, with a CAGR of 6.46%, reaching USD 8.42 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.78 billion
Estimated Year [2025] USD 6.13 billion
Forecast Year [2030] USD 8.42 billion
CAGR (%) 6.46%

The fibrotic diseases treatment market represents a dynamic and evolving segment of the healthcare industry, characterized by its focus on combating complex diseases marked by tissue scarring and organ dysfunction. Over the years, increased research, technological innovations, and a growing understanding of disease mechanisms have spurred significant advancements in treatment approaches. This comprehensive analysis dives deep into robust market insights, emphasizing the clinical, therapeutic, and economic implications of therapies across various fibrotic conditions. It offers a detailed overview of key drivers, challenges, and emerging trends that are reshaping treatment paradigms. Stakeholders, ranging from clinical practitioners to decision-makers, will find the ensuing discussions engaging and insightful, revealing a market landscape that is both challenging and ripe with transformative opportunities.

In recent times, healthcare systems have witnessed rapid integration of advanced technologies and personalized treatment regimes aimed at targeting fibrotic pathways more effectively. This transition, supported by evolving regulatory landscapes and an increased focus on patient-centric approaches, has paved the way for groundbreaking therapeutic advancements. As the incidence of chronic fibrotic conditions continues to rise, the market's focus on innovation, safety, and clinical efficacy remains paramount. The analysis presented in this report is designed to offer a granular understanding of these dynamics, ensuring that every stakeholder is well-equipped to navigate and capitalize on the unfolding opportunities in this intricate field.

Transformative Shifts in the Treatment Paradigm

The landscape of fibrotic diseases treatment is experiencing a period of significant transformation, driven by several interconnected shifts that are redefining the market. Foremost among these is the surge in clinical research innovations, where breakthroughs in understanding cellular mechanisms and molecular processes have led to the development of targeted therapies. This evolution is not only shifting treatment protocols but also fostering a more personalized approach to care that is closely aligned with individual patient needs. In parallel, there has been a notable push towards integrating digital health solutions, which facilitate precise diagnosis and real-time monitoring of treatment efficacy.

The adoption of these innovations has spurred regulatory bodies to revisit and reshape approval pathways, ensuring that emerging therapies meet stringent safety and efficacy standards. Enhanced collaboration between industry stakeholders, academic researchers, and medical institutions has accelerated market penetration of novel interventions, further underscoring the transformative impact of these shifts. The convergence of these factors is creating a landscape where traditional paradigms are being challenged by scientifically driven, technology-enabled treatment models. As healthcare providers increasingly leverage big data, AI-driven analytics, and genomics, the promise of improved patient outcomes and refined treatment protocols becomes ever more tangible. This paradigm shift, marked by its emphasis on precision medicine and adaptive treatment strategies, characterizes the market's response to ever-evolving clinical needs and underscores the vital role of continuous innovation in reshaping patient care.

Key Segmentation Insights in the Fibrotic Diseases Treatment Market

An in-depth analysis of the fibrotic diseases treatment market reveals a multifaceted segmentation that dives into clinical, technological, and operational dimensions. The segmentation based on type provides a detailed exploration of diverse conditions such as cardiac fibrosis, liver fibrosis, pulmonary fibrosis, and renal fibrosis, each presenting unique challenges and therapeutic considerations. These distinctions are crucial for tailoring intervention strategies and optimizing resource allocation in various patient care scenarios.

Further segmentation by treatment type distinguishes between conventional medication, organ transplantation procedures, and innovative oxygen therapy techniques. This classification underscores the diversity in treatment modalities, reflecting shifts in clinical practices towards more refined and targeted approaches. The market's segmentation regarding administration methods-ranging from inhalation, injection, intravenous, oral, to topical methods-illustrates the wide range of application techniques that cater to different clinical approvals and patient compliance models. This segmentation serves as a blueprint to understand the varying levels of invasiveness, efficacy, and cost implications that each method presents.

Additional segmentation by treatment stage identifies patient journeys through advanced-stage fibrosis, early-stage fibrosis, end-stage organ failure, and pre-fibrosis scenarios where preventative treatment is key. This dimension highlights the evolution of therapeutic interventions and emphasizes the importance of early diagnosis and proactive management in mitigating disease progression. Finally, segmentation based on the end user brings into focus the roles of key healthcare settings such as academic and research institutes, hospitals, and specialty clinics. These segments are integral in the dissemination of cutting-edge clinical knowledge, the coordination of care, and the drive towards innovation. Collectively, these segmentation insights provide a granular understanding of market trends, revealing critical intersections between clinical need, treatment innovation, and healthcare delivery models.

Based on Type, market is studied across Cardiac Fibrosis, Liver Fibrosis, Pulmonary Fibrosis, and Renal Fibrosis.

Based on Treatment Type, market is studied across Medication, Organ Transplantation, and Oxygen Therapy.

Based on Administration Method, market is studied across Inhalation, Injection, Intravenous, Oral, and Topical.

Based on Treatment Stage, market is studied across Advanced-Stage Fibrosis, Early-Stage Fibrosis, End-Stage Organ Failure, and Pre-Fibrosis (Preventative Treatment).

Based on End User, market is studied across Academic & Research Institutes, Hospitals, and Specialty Clinics.

Key Regional Insights: Global Perspectives on Market Dynamics

The global fibrotic diseases treatment market demonstrates significant regional variations, each contributing unique insights into market trends and healthcare innovations. In the Americas, robust healthcare infrastructure and an environment that fosters extensive clinical research have accelerated the adoption of advanced treatment modalities. This region is characterized by its high healthcare spending, progressive regulatory frameworks, and the presence of leading clinical research institutions that collectively drive accelerated market maturity. The regional focus on patient-centric care and widespread insurance coverage further amplify the adoption of targeted treatment strategies and novel intervention techniques.

Across Europe, the Middle East, and Africa, diverse factors shape the market dynamics, ranging from varied economic landscapes to significant regulatory heterogeneity. This collection of regions presents an intriguing mix of mature healthcare systems alongside rapidly evolving medical practices. The emphasis on disease prevention and early intervention, coupled with a strong push towards technology-driven diagnostics, is fostering an environment ripe for innovation. Moreover, strategic partnerships across academic institutions and pharmaceutical companies in these regions have resulted in rapid knowledge transfer and the expedited introduction of efficacious treatment options to clinical practice.

The Asia-Pacific region stands out for its rapid expansion of healthcare infrastructure, driven by burgeoning economies and increasing investments in medical research. With a growing middle class and heightened awareness about chronic diseases, this region has emerged as a critical hub for clinical trials and translational research in fibrotic diseases. The blend of traditional and modern therapeutic approaches has not only diversified treatment protocols but also positioned the market for sustained growth. Region-specific initiatives aimed at healthcare democratization and improved accessibility have further catalyzed the adoption of innovative treatment models. Collectively, these regional insights reveal a complex, yet highly dynamic, global market landscape where local innovations meet global best practices to drive comprehensive advancements in fibrotic diseases treatment.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Insights from Leading Market Players

The competitive landscape of the fibrotic diseases treatment market is defined by contributions from an array of leading companies that have consistently driven innovation and market growth. Industry frontrunners such as AbbVie Inc., Amgen Inc., Baxter International Inc., and Biogen Inc. have been instrumental in pioneering advancements in therapeutic modalities and enhancing patient care outcomes. Major players including Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, and Eli Lilly and Company have leveraged extensive research and development pipelines to introduce groundbreaking treatment options that address complex fibrotic pathways.

This landscape is further enriched by companies like Ferring Pharmaceuticals Private Limited, Gilead Sciences, Inc., and GlaxoSmithKline plc, which have integrated cutting-edge technology and robust clinical trials into their treatment portfolios. Collaboration and strategic investments by Ipsen Pharma and Kyorin Pharmaceutical Co., Ltd. have also significantly contributed to evolving treatment protocols and expanding drug accessibility. The market's momentum is additionally amplified by the initiatives from Mallinckrodt, Merck & Co., Inc., and Mitsubishi Tanabe Pharma Corporation, whose concerted efforts in clinical research have paved the way for pioneering therapeutic interventions.

Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., and Sanofi S.A. continue to redefine industry standards through innovative research, clinical excellence, and strategic partnerships. The impact of Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A. further underscores a collaborative commitment to advancing treatment paradigms. These industry leaders, with their expansive global networks and emphasis on precision medicine, have not only enriched the competitive landscape but have also set a high benchmark for quality and efficacy in fibrotic diseases treatment. Their contributions, grounded in rigorous clinical research and sustained investment in innovation, continue to shape the market's trajectory and highlight the importance of an integrated approach in addressing the multifaceted challenges associated with fibrotic disease management.

The report delves into recent significant developments in the Fibrotic Diseases Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Baxter International Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Ferring Pharmaceuticals Private Limited, Gilead Sciences, Inc., GlaxoSmithKline plc, Ipsen Pharma, Kyorin Pharmaceutical Co., Ltd., Mallinckrodt, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A.. Actionable Recommendations for Industry Leaders

Industry leaders must adopt a proactive strategy that blends clinical innovation with market responsiveness to capitalize on emerging opportunities in fibrotic diseases treatment. First, enhancing investment in research and development is essential, with particular emphasis on next-generation diagnostic tools and personalized treatment regimens. Leaders should leverage advanced analytics to gain deeper insights into patient profiles and disease progression dynamics, effectively tailoring treatment protocols to improve clinical outcomes. Embracing information technology to integrate real-time data from clinical trials and patient feedback can further refine product development and ensure rapid iteration of therapeutic strategies.

Moreover, forging collaborative partnerships with academic institutions and research organizations will facilitate the sharing of critical knowledge and accelerate the translation of scientific breakthroughs into market-ready therapies. By establishing dedicated innovation hubs and cross-functional teams, organizations can better navigate the complex regulatory environment and ensure that their products meet both market expectations and stringent safety standards.

In addition, expanding geographical reach through strategic regional alliances holds significant promise. The juxtaposition of mature and emerging markets offers periods of competitive advantage that can be harnessed by tailoring solutions to region-specific needs. Industry leaders must also focus on robust market education programs to raise awareness about the latest advancements in fibrotic diseases treatment, thereby driving both demand and patient engagement. Comprehensive training for healthcare practitioners on the efficacy, mechanism of action, and safety profiles of new treatments will be critical in building trust and accelerating adoption across clinical settings.

Finally, companies must remain agile in responding to evolving market trends. This involves continuous monitoring of competitive dynamics, regulatory shifts, and technological advancements. A dynamic approach to risk management-coupled with strategic resource allocation and consistent stakeholder engagement-can help navigate uncertainties while ensuring sustained growth and innovation in this rapidly evolving landscape.

Conclusion: Synthesizing Critical Market Insights

The overall analysis of the fibrotic diseases treatment market uncovers an intricate tapestry of innovation, regional dynamics, and competitive collaboration. Through a detailed exploration of clinical segmentation, it becomes evident that diverse treatment pathways are tailored to address the distinct challenges presented by various fibrotic conditions. By aligning patient-centric treatment approaches with modern delivery methods, the market is making significant strides towards improving therapeutic outcomes and enhancing the quality of life for affected individuals.

The transformative shifts in the treatment landscape highlight the increasing importance of precision medicine, leveraging technological advancements such as advanced diagnostic tools, AI-driven analytics, and digital health integrations. These shifts not only ensure greater clinical accuracy but also pave the way for earlier interventions, thereby mitigating disease progression and reducing long-term healthcare costs. The integration of such innovations into clinical practice is critical for managing both early-stage interventions and late-stage treatment challenges.

Furthermore, a global perspective reveals that while mature markets in the Americas and Europe, Middle East & Africa benefit from established healthcare infrastructures and research capabilities, the Asia-Pacific region is rapidly emerging as a pivotal market with burgeoning opportunities for growth. The seamless blend of innovative treatment technologies and evolving healthcare policies across these regions underscores a unified drive towards holistic and comprehensive care.

In summary, the convergence of detailed segmentation insights, regional market analyses, and a robust competitive landscape consolidates the understanding of current trends and future directions in the fibrotic diseases treatment market. Strategic investments, agile market approaches, and an unwavering commitment to clinical excellence will remain the cornerstones of growth, innovation, and sustained market success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of fibrotic diseases due to aging populations and lifestyle factors
      • 5.1.1.2. Expansion of global healthcare infrastructure improving access to fibrotic diseases treatment
      • 5.1.1.3. Supportive regulatory policies and expedited approval pathways for novel fibrotic therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with drug development and clinical trial phases limiting new treatment entries
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of digital health technologies enhancing disease monitoring and treatment adherence
      • 5.1.3.2. Advancements in precision medicine and targeted treatment approaches for fibrotic conditions
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory approval processes and compliance burdens for novel fibrotic treatment solutions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Rising consumption of medications for the treatment of fibrotic conditions
    • 5.2.2. End User: Increasing focus on the early-stage research of fibrotic diseases treatments in academic & research institutes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fibrotic Diseases Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Cardiac Fibrosis
  • 6.3. Liver Fibrosis
  • 6.4. Pulmonary Fibrosis
  • 6.5. Renal Fibrosis

7. Fibrotic Diseases Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Medication
  • 7.3. Organ Transplantation
  • 7.4. Oxygen Therapy

8. Fibrotic Diseases Treatment Market, by Administration Method

  • 8.1. Introduction
  • 8.2. Inhalation
  • 8.3. Injection
  • 8.4. Intravenous
  • 8.5. Oral
  • 8.6. Topical

9. Fibrotic Diseases Treatment Market, by Treatment Stage

  • 9.1. Introduction
  • 9.2. Advanced-Stage Fibrosis
  • 9.3. Early-Stage Fibrosis
  • 9.4. End-Stage Organ Failure
  • 9.5. Pre-Fibrosis (Preventative Treatment)

10. Fibrotic Diseases Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Fibrotic Diseases Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Fibrotic Diseases Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Fibrotic Diseases Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Mediar Therapeutics secures global licensing with Lilly in a USD 99 million upfront deal to expand its treatment pipeline for fibrotic diseases
    • 14.3.2. Relation partners with GSK for accelerating breakthrough fibrotic disease and osteoarthritis treatments
    • 14.3.3. Madrigal Pharmaceutical secures accelerated FDA approval for Rezdiffra as a groundbreaking noncirrhotic NASH treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Baxter International Inc.
  • 4. Biogen Inc.
  • 5. Boehringer Ingelheim International GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. Ferring Pharmaceuticals Private Limited
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline plc
  • 11. Ipsen Pharma
  • 12. Kyorin Pharmaceutical Co., Ltd.
  • 13. Mallinckrodt
  • 14. Merck & Co., Inc.
  • 15. Mitsubishi Tanabe Pharma Corporation
  • 16. Novartis International AG
  • 17. Pfizer Inc.
  • 18. Regeneron Pharmaceuticals, Inc.
  • 19. Sanofi S.A.
  • 20. Santen Pharmaceutical Co., Ltd.
  • 21. Takeda Pharmaceutical Company Limited
  • 22. Teva Pharmaceutical Industries Ltd.
  • 23. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. FIBROTIC DISEASES TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. FIBROTIC DISEASES TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. FIBROTIC DISEASES TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. FIBROTIC DISEASES TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. FIBROTIC DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. FIBROTIC DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FIBROTIC DISEASES TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FIBROTIC DISEASES TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY CARDIAC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY LIVER FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY PULMONARY FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY RENAL FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADVANCED-STAGE FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY EARLY-STAGE FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END-STAGE ORGAN FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY PRE-FIBROSIS (PREVENTATIVE TREATMENT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. FIBROTIC DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 241. FIBROTIC DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024